Finally, we compared the BCL-2 expression and function of the peripheral T cells derived from 12 matched patients with CLL pre- and post-venetoclax treatment (Fig. 8a–e). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.